Bioequivalence of Two Tablet Forms of MK0974 (0974-045)
Phase 1
Completed
- Conditions
- Migraine
- Interventions
- Drug: MK0974 Ethanolate formulation
- Registration Number
- NCT00965887
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
This study will evaluate the bioequivalence of two solid dose formulations of MK0974.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
- Subject is in good health
- Subject is a non-smoker
- Subject is willing to comply with the study restrictions
Read More
Exclusion Criteria
- Subject has a history of stroke, chronic seizures, or major neurological disorder
- Subject has a history of cancer
- Subject is a nursing mother
- Subject has or has a history of any disease or condition that might make participation in the study unsafe or that might confound the results of the study
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description 1 MK0974 Ethanolate formulation MK0974 Ethanolate
- Primary Outcome Measures
Name Time Method Area under the curve (AUC(0 to infinity) following single dose administration of MK0974 ethanolate or hydrate formulations Through 48 hours postdose Peak plasma concentration (Cmax) following single dose administration of MK0974 ethanolate or hydrate formulations Through 48 Hours Post Dose
- Secondary Outcome Measures
Name Time Method